Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company. The Company is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Its diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. KidneyIntelX is a bioprognostic methodology. The Company is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations, and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)